While prevention is a bedrock of public health, innovative therapeutics are needed to
complement the armamentarium of interventions required to achieve disease control and …

Chagas disease is a neglected tropical disease and a global public health issue. In terms of
treatment, no progress has been made since the 1960s, when benznidazole and nifurtimox …

Chronic Trypanosoma cruzi infections are typically lifelong, with small numbers of parasites
surviving in restricted tissue sites, which include the gastrointestinal tract. There is …

Infections with Trypanosoma cruzi are usually lifelong despite generating a strong adaptive
immune response. Identifying the sites of parasite persistence is therefore crucial to …

Investigations into intracellular replication and differentiation of Trypanosoma cruzi within
the mammalian host have been restricted by limitations in our ability to detect parasitized …

Since the first published genome sequence of Trypanosoma cruzi in 2005, there have been
tremendous technological advances in genomics, reverse genetics, and assay development …

Trypanosoma cruzi is the etiological agent of Chagas disease. Following T cell-mediated
suppression of acute-phase infection, this intracellular eukaryotic pathogen persists long …

Numerous works have demonstrated that trypanosomatid motility is relevant for parasite
replication and sensitivity. Nonetheless, although some findings indirectly suggest that …

Chagas disease is caused by Trypanosoma cruzi, a protozoan parasite that displays
considerable genetic diversity. Infections result in a range of pathological outcomes, and …

Chagas disease is caused by infection with the protozoan parasite Trypanosoma cruzi (T.
cruzi), an intracellular pathogen that causes significant morbidity and death among millions …